 Norwood, MA, June 24, 2021 GLOBE NEWSWIRE -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ: CRBP Corbus or the Company, an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the Phase 3 D ETER M INE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. 